{"id":12146,"date":"2018-10-26T00:00:00","date_gmt":"2018-10-26T00:00:00","guid":{"rendered":"http:\/\/medgoo.com\/index.php\/2018\/10\/26\/high-coverage-rollout-of-prep-tied-to-drop-in-hiv-diagnoses\/"},"modified":"2018-10-29T16:01:21","modified_gmt":"2018-10-29T16:01:21","slug":"high-coverage-rollout-of-prep-tied-to-drop-in-hiv-diagnoses","status":"publish","type":"post","link":"https:\/\/medgoo.com\/index.php\/2018\/10\/26\/high-coverage-rollout-of-prep-tied-to-drop-in-hiv-diagnoses\/","title":{"rendered":"High-Coverage Rollout of PReP Tied to Drop in HIV Diagnoses"},"content":{"rendered":"<h3>Pre-exposure prophylaxis implementation linked to rapid decline in HIV diagnoses among MSM<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>FRIDAY, Oct. 26, 2018 (HealthDay News) &#8212; A rapid, targeted, high-coverage rollout of HIV pre-exposure prophylaxis (PrEP) is associated with a decrease in HIV diagnoses among high-risk men who have sex with men (MSM), according to a study published online Oct. 17 in <i>The Lancet<\/i>.<\/p>\n<p>Andrew E. Grulich, Ph.D., from the University of New South Wales in Australia, and colleagues recruited high-risk gay and bisexual men in a network of 21 clinics in an implementation cohort study of daily co-formulated tenofovir disoproxil fumarate and emtricitabine as HIV PrEP. Protocol-specified co-primary outcomes (within-cohort HIV incidence and change in population HIV diagnoses between the 12-month periods before and after PrEP rollout) were reported 12 months after recruitment of 3,700 participants.<\/p>\n<p>The researchers found that two men became infected with HIV over 4,100 person-years (incidence, 0.048 per 100 person-years); both of the men had been nonadherent to PrEP. In New South Wales, there was a reduction in HIV diagnoses in MSM from 295 in the 12 months before PrEP rollout to 221 in the 12 months after (relative risk reduction, 25.1 percent; 95 percent confidence interval, 10.5 to 37.4 percent). Declines were seen in recent HIV infections (from 149 to 102; relative risk reduction, 31.5 percent; 95 percent confidence interval, 11.3 to 47.3 percent) and in other HIV diagnoses (from 146 to 119; relative risk reduction, 18.5 percent; 95 percent confidence interval, \u22124.5 to 36.6 percent).<\/p>\n<p>&#8220;Rapid, targeted, high-coverage rollout to scale was accompanied by rapid reductions in HIV incidence at the population level,&#8221; the authors write. &#8220;PrEP is a highly effective element of the combination prevention approach in MSM.&#8221;<\/p>\n<p>Several authors disclosed ties to the pharmaceutical industry, including Gilead Sciences, which partially funded the study.<\/p>\n<p><a href=\" https:\/\/www.thelancet.com\/journals\/lanhiv\/article\/PIIS2352-3018(18)30215-7\/fulltext \" target=\"_new\">Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n<p><a href=\" https:\/\/www.thelancet.com\/journals\/lanhiv\/article\/PIIS2352-3018(18)30253-4\/fulltext \" target=\"_new\">Editorial (subscription or payment may be required)<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2018 <a href=\"https:\/\/www.healthday.com\/\" target=\"_new\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pre-exposure prophylaxis implementation linked to rapid decline in HIV diagnoses among MSM<\/p>\n","protected":false},"author":6,"featured_media":12183,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[11],"class_list":["post-12146","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"_links":{"self":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/12146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/comments?post=12146"}],"version-history":[{"count":0,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/12146\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media\/12183"}],"wp:attachment":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media?parent=12146"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/categories?post=12146"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/tags?post=12146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}